Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094554 | 0.86 | EGFR (0.81) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL691455 | 0.86 | EGFR (0.78) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL5528646 | 0.81 | EGFR (0.66) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL690989 | 0.80 | EGFR (0.65) | EGFRERBB2ERBB4 | |
| SCHEMBL691623 | 0.80 | EGFR (0.82) | EGFRERBB2ERBB4 | |
| SCHEMBL2179448 | 0.79 | EGFR (0.60) | EGFRERBB2ERBB3 | |
| SCHEMBL2177111 | 0.78 | EGFR (0.70) | EGFRERBB2ERBB3 | |
| SCHEMBL1105303 | 0.78 | EGFR (0.80) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL5005468 | 0.78 | EGFR (0.80) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL9975357 | 0.78 | EGFR (0.65) | EGFRERBB2GAKERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |